You might also like
Beam Therapeutics Inc. is a biotechnology company specializing in precision genetic medicines. It develops therapies using its proprietary base editing technology to address serious genetic diseases. The company primarily generates revenue through license and collaboration agreements with partners.
- License and Collaboration Agreements - Provides genetic medicine solutions through partnerships with companies like Pfizer, Apellis, Verve, and Orbital, contributing to research and development activities.
- Base Editing Technology - Enables precise genetic modifications by targeting single DNA bases without creating double-stranded breaks, offering predictable and efficient outcomes.
- Delivery Modalities - Develops tailored delivery systems for gene correction, silencing, activation, and multiplex editing, applicable to both ex vivo and in vivo approaches.
- Therapeutic Programs - Focuses on treatments for hematology and genetic diseases, including BEAM-101 for sickle cell disease and beta-thalassemia, and BEAM-302 for alpha-1 antitrypsin deficiency.
- Pipeline Expansion - Advances additional programs targeting glycogen storage disease type 1a and T-cell acute lymphoblastic leukemia.
- Internal Manufacturing - Operates a commercial-scale cGMP facility in North Carolina to support production of product candidates.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
John Evans ExecutiveBoard | Chief Executive Officer | Member of the Board of Directors at Orbital Therapeutics, Inc. | John Evans has served as the Chief Executive Officer and Board Director of Beam Therapeutics since January 2017. He brings extensive industry experience from external roles, including his current board position at Orbital Therapeutics since September 2022. | View Report → |
Amy Simon Executive | Chief Medical Officer | Amy Simon, M.D. is the Chief Medical Officer at Beam Therapeutics since March 22, 2021. She has extensive experience in clinical development, having previously served as Vice President of Clinical Development at Alnylam Pharmaceuticals from 2010 to 2021. | ||
Christine Bellon Executive | Chief Legal Officer and Secretary | Christine Bellon, Ph.D., has served as Chief Legal Officer and Secretary at Beam Therapeutics since April 2019 and holds extensive legal and corporate governance experience from previous leadership roles in the biotechnology sector. | ||
Giuseppe Ciaramella Executive | President | Interim Chief Executive Officer at Orbital Therapeutics, Inc. (since March 2022) ; Board Member at Orbital Therapeutics, Inc. (since March 2022) | Giuseppe Ciaramella, Ph.D., has been the President of Beam Therapeutics since January 2020 and previously served as the Chief Scientific Officer from February 2018 to February 2023. He also holds an external role as Interim Chief Executive Officer and Board Member at Orbital Therapeutics, Inc. since March 2022. | |
Sravan K. Emany Executive | Chief Financial Officer (CFO) | Member of the Board of Directors at Assertio Holdings, Inc. | Sravan K. Emany has served as the Chief Financial Officer at Beam Therapeutics Inc. since December 19, 2024. He brings over two decades of financial leadership experience, having previously held executive roles at Ironwood Pharmaceuticals and Integra LifeSciences, and he serves as a board member at Assertio Holdings, Inc.. | |
Carole Ho Board | Board Member | Chief Medical Officer and Head of Development at Denali Therapeutics (June 2015); Board Member at NGM Biopharmaceuticals, Inc. (June 2020) | Carole Ho, M.D., has served as a Board Member at Beam Therapeutics since November 2018 and has extensive experience as Chief Medical Officer and Head of Development at Denali Therapeutics since June 2015. | |
Chirfi Guindo Board | Member of the Board of Directors | Chief Marketing Officer, Human Health at Merck & Co., Inc. | Chirfi Guindo is a seasoned executive with extensive experience in global strategy and healthcare. He is currently a Board Member at Beam Therapeutics since December 2, 2024 while concurrently serving as Chief Marketing Officer, Human Health at Merck & Co., Inc. (appointed in 2024), and previously served as Executive Vice President at Biogen from 2017 to 2024. | |
Christi Shaw Board | Member of the Board of Directors | Director of Avantor, Inc.; Director of ReAlta Life Sciences, Inc. | Christi Shaw joined Beam Therapeutics as a Board Director in December 2023 and serves on both the Audit and Nominating & Corporate Governance Committees, bringing over 30 years of leadership experience in the biopharmaceutical industry. | |
Graham Cooper Board | Board Member | Chairman of the Board of Directors of Kezar Life Sciences, Inc. | Graham Cooper has served as a Board Member at Beam Therapeutics since October 2019 and is the Audit Committee Chair, providing valuable oversight in accordance with Nasdaq independence standards. | |
John Maraganore Board | Board of Directors Member | Kymera Therapeutics (Board) ; Takeda Pharmaceuticals (Board) ; ProKidney Corp. (Board) ; Agios Pharmaceuticals (Board) ; Arch Venture Partners (Advisory) ; Atlas Venture (Advisory) ; RTW Investments (Advisory) | John Maraganore, Ph.D., has served on Beam Therapeutics' Board of Directors since November 2021 and chairs its nominating and corporate governance committee. He has a distinguished career in biotechnology, previously leading executive roles at companies including Alnylam Pharmaceuticals. | |
Kathleen Walsh Board | Director on the Board | Secretary of Health and Human Services, Commonwealth of Massachusetts; Member, Boston Public Health Commission; Member, Massachusetts Hospital Association; Member, Yale University; Member, Association of American Medical Colleges; Member, Pine Street Inn | Kathleen Walsh serves as an independent director on the Board of Beam Therapeutics since January 2021. She brings extensive expertise in healthcare administration as seen in her active role as Secretary of Health and Human Services, Commonwealth of Massachusetts, and her previous leadership as CEO of Boston Medical Center from March 2010 to February 2023. | |
Kristina Burow Board | Class I Director on the Board of Directors | Managing Director at ARCH Venture Partners | Kristina Burow has served on the Beam Therapeutics Board of Directors since June 2017 as a Class I director and also chairs the Compensation Committee, with her term expiring in 2024. | |
Mark Fishman Board | Director and Lead Independent Director | Skyline Therapeutics Board Member; EmbarkNeuro Board Member; Versanis Bio Board Member; Co-Founding Partner and Chairman, Scientific and Medical Advisory Board, Aditum Bio Fund | Mark Fishman, M.D., has a distinguished career in medicine, biotechnology, and academia. He has served as Founding President at NIBR and held leadership roles at Semma Therapeutics and Aditum Bio Fund before joining BEAM as Director and Lead Independent Director in May 2018. |
-
With the unfortunate patient death attributed to busulfan conditioning, have you considered making changes to your screening criteria or conditioning regimen to mitigate such risks in future patients?
-
If the ESCAPE program does not achieve its intended efficacy or fails to become a game-changing therapy, how does that impact your commitment to commercializing BEAM-101 independently, and would you consider partnering or out-licensing it?
-
Considering the potential for BEAM-101 to be cannibalized by the ESCAPE program due to its improved safety profile, how are you strategizing the sequencing and commercialization of these two products to maximize their market potential?
-
Given the heterogeneity of the alpha-1 antitrypsin deficiency patient population, how are you addressing the different regulatory pathways and clinical endpoints required for patients with lung versus liver phenotypes, and how does this impact your enrollment and commercialization strategy?
-
With initial BEAM-101 clinical data showing elevated total hemoglobin levels in patients, is there concern about potential long-term effects of sustained high hemoglobin levels, and how are you monitoring and addressing this in your clinical trials?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
PerkinElmer | There are several other companies utilizing base editing technology, including this company. |
Life Edit | There are several other companies utilizing base editing technology, including this company, which is an ElevateBio company. |
Metagenomi | There are several other companies utilizing base editing technology, including this company. |
There are several other companies utilizing base editing technology, including this company. | |
There are several other companies utilizing base editing technology, including this company. | |
For sickle cell disease, these companies include this company. | |
For sickle cell disease, these companies include this company. | |
For sickle cell disease, these companies include this company. | |
For sickle cell disease, these companies include this company. | |
Kamau Therapeutics | For sickle cell disease, these companies include this company. |
For sickle cell disease, these companies include this company. | |
Tessera Therapeutics | For sickle cell disease, these companies include this company. |
Cimeio Therapeutics | For sickle cell disease, these companies include this company. |
For sickle cell disease, these companies include this company. | |
Wave Life Sciences | For AATD targeted therapies, these companies include this company. |
For AATD targeted therapies, these companies include this company. | |
Korro Bio | For AATD targeted therapies, these companies include this company. |
For AATD targeted therapies, these companies include this company. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Guide Therapeutics, Inc. | 2021 | Beam Therapeutics acquired Guide Therapeutics through a two-step merger completed on February 22, 2021. The deal involved an upfront consideration of $120 million in Beam common stock and potential milestone payments up to $320 million, strategically enhancing Beam’s precision genetic medicine platform by integrating Guide’s proprietary LNP screening technology. |
Recent press releases and 8-K filings for BEAM.
- Beam Therapeutics announced Q1 2025 financial results, with a cash position of $1.2 billion and a net loss of approximately $109 million.
- The company advanced its clinical programs by dosing the first patient in the BEAM-301 trial for GSDIa, accepting BEAM-101 data for presentation at EHA 2025, and initiating BEAM-302 dosing after FDA IND clearance.
- A recent $500 million financing has extended the cash runway into 2028, reinforcing its capability to support upcoming research and clinical milestones.
- BEAM-302 data update: The company presented early clinical data from its dose escalation phase for its in vivo base editing therapy targeting AAT deficiency, showing a safe profile across 15, 30, and 60 mg cohorts with dose-responsive increases in total AAT and a conversion to 88% M protein at the highest dose.
- Potential for further efficacy gains: The data indicate that additional dose escalations may achieve even higher therapeutic AAT levels (potentially approaching 20 micromolar), leveraging a steep sigmoidal dose-response curve and robust fold-change improvements.
- Validated proprietary platform & pipeline expansion: Beam’s proprietary lipid nanoparticle delivery system was highlighted as a key asset, with its successful application in both BEAM-302 and the promising BEAM-101 program for sickle cell disease, positioning the company for broader liver-targeted therapies.
- BEAM-302 Clinical Milestone: First genetic correction of an AATD-causing mutation achieved with durable, dose-dependent increases in total/functional AAT (12.4 µM at 60 mg; 78% reduction in mutant Z-AAT) .
- $500M Financing & Equity Offering: Oversubscribed offering boosts cash & securities to $850.7M, with issuance of shares and pre-funded warrants targeting approximately $500M in gross proceeds, extending runway into 2028 .
- Innovative Lifetime Therapy: CEO John Evans detailed BEAM-302’s ability to convert severe ZZ patients into a carrier profile with predominantly functional M protein, raising AAT levels above the therapeutic threshold (12.5 µM and climbing) .
- Patient-Centric Approach: BEAM-302 is a single-administration, lifetime therapy designed to expedite accelerated approval, enhance patient convenience, and tap into significant global market opportunities .
- Safety & Next Steps: Favorable safety profile observed across dose cohorts; additional dose escalation, new liver-targeted programs, and further data presentations (including a call on March 10, 2025) are planned, with the offering expected to close on or about March 11, 2025 .
- Achieved key clinical milestones: The company met its adult enrollment target for the BEACON trial of BEAM-101, with dosing of 30 patients expected by mid-2025 and additional clinical trial milestones for BEAM-302, BEAM-301, and BEAM-103 scheduled through 2025.
- Strong financial position: Reported cash, cash equivalents, and marketable securities stood at $850.7 million as of December 31, 2024, supporting operating plans into 2027, alongside detailed updates on R&D and G&A expenses.
- Clinical Pipeline Progress: BEAM-101 dosing over 40 patients (with 30 dosing by mid‑2025) and promising early data from BEAM-302 (alpha‑1 antitrypsin deficiency) and BEAM-301 (glycogen storage disease 1a) with key clinical milestones expected in 2025 .
- Robust Financial Position: Reported $850.7M in cash, cash equivalents, and marketable securities as of December 31, 2024, supporting operations into 2027 .
- Pipeline Innovation: Initiatives include the ESCAPE platform with plans to launch a Phase 1 healthy volunteer trial for BEAM-103 by year‑end 2025 .
- Operational Achievements: CEO John Evans emphasized efficient ex vivo manufacturing, rapid engraftment with fewer hospital days, and non‑chemotherapy conditioning to enhance patient outcomes .
- Gene Editing Delivery: Advances in in vivo gene editing via lipid nanoparticles (LNPs) highlight future catalyst-rich opportunities and collaborations .